EUVIMEDEUVIMED entdecken
Open Access

Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer

James C Dickerson iD, Marcus T Moen, Perry Nielsen, Fauzia Riaz iD, Edward Tran iD, Jennifer L Caswell-Jin iD, Wesley Suen iD, Jeremy D Goldhaber-Fiebert, Fernando Alarid-Escudero iD

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-01960 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von James C Dickerson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Hematology and Oncology), Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Drug Costs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Creating value-aligned treatment pathways in breast cancer requires understanding the cost and cost-effectiveness of new therapies. To address uncertainty in the optimal treatment sequence, we developed a decision model to assess the cost-effectiveness of various treatment sequences for patients with human epidermal growth factor receptor 2 (HER2)–low metastatic breast cancer who are eligible for trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) under current US Food and Drug Administration labeling. METHODS We derived disease progression and therapy data from the Destiny-Breast04 trial and sourced cost and quality-of-life data from the published literature. Our simulation modeled 57-year-old women with HER2-low, endocrine refractory, and triple-negative metastatic breast cancer eligible for third-line treatment. We evaluated four sequences: chemotherapy (chemo) → chemo, T-DXd → chemo, chemo → T-DXd, and T-DXd → SG. Outcomes included quality-adjusted life years (QALYs), total lifetime costs (2020 US dollars [USD], 3% annual discount), and incremental cost-effectiveness ratios. Sequences that cost

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDrug CostsHumansFemaleCost-Benefit AnalysisMiddle AgedQuality-Adjusted Life YearsTrastuzumabNeoplasm MetastasisCamptothecinAntibodies, Monoclonal, HumanizedQuality of LifeImmunoconjugates

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabCamptothecinAntibodies, Monoclonal, HumanizedImmunoconjugatesERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Medicine (Hematology and Oncology), Stanford University, Stanford, CA.
  • Department of Health Policy, Stanford University, Stanford, CA.
  • Department of Management Science and Engineering, Stanford University, Stanford, CA.
  • Department of Computer Science, Stanford University, Stanford, CA.
  • Department of Biology, Stanford University, Stanford, CA.

ORCID-Profile: James C Dickerson, Fauzia Riaz, Edward Tran, Jennifer L Caswell-Jin, Wesley Suen, Fernando Alarid-Escudero

Förderung

  • AHRQ HHS

Zitieren

APA

Dickerson, J. C., Moen, M. T., Nielsen, P., Riaz, F., Tran, E., Caswell-Jin, J. L., Suen, W., Goldhaber-Fiebert, J. D., & Alarid-Escudero, F. (2025). Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01960

Vancouver

Dickerson JC, Moen MT, Nielsen P, Riaz F, Tran E, Caswell-Jin JL, et al. Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01960

BibTeX
@article{Dickerson2025,
  author = {Dickerson, James C and Moen, Marcus T and Nielsen, Perry and Riaz, Fauzia and Tran, Edward and Caswell-Jin, Jennifer L and Suen, Wesley and Goldhaber-Fiebert, Jeremy D and Alarid-Escudero, Fernando},
  title = {Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-01960}
}
Kostenlos starten →